RADIANCE I – Rating Atherosclerosis Disease Change by Imaging with a New CETP Inhibitor 1 Trial
Principal contacts
Michiel L. Bots - University Medical Center Utrecht, Utrecht, the Netherlands
Diederick E. Grobbee - University Medical Center Utrecht, Utrecht, the Netherlands
Frank L. J. Visseren - University Medical Center Utrecht, Utrecht, the Netherlands
John J. P. Kastelein - University of Amsterdam, Amsterdam, the Netherlands
Study design
The Rating Atherosclerosis Disease Change by Imaging with a New CETP Inhibitor 1 Trial (RADIANCE I) is a two-arm clinical trial based at 37 recruitment and imaging centres in North America, Europe, and South Africa. The principal aim of the trial was to investigate the effect of Atorvastatin and placebo versus Atorvastatin and Torcetrapib (60mg/day) on carotid atherosclerosis progression in patients with heterozygous familial hypercholesterolaemia. Individuals were eligible for inclusion if they were aged between 18 and 70 years with heterozygous familial hypercholesterolaemia. The study was approved by the Institutional Review Board. Informed consent was obtained from all subjects before randomization.
Link to study webpage – https://clinicaltrials.gov/ct2/show/NCT00136981
Key publications
Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis. Curr Med Res Opin. 2007 Apr;23(4):885-94
Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia. N Engl J Med. 2007 Apr 19;356(16):1620-30